Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Taylor & Francis
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950458/ |